ResearchCompounds,verified.

Bromazolam is a synthetic compound belonging to the triazolobenzodiazepine class — a structural group characterised by the fusion of a benzene ring, a seven-membered diazepine ring, and a 1,2,4-triazole ring. It is closely related to established benzodiazepine research compounds and shares their fundamental mechanism of action at GABA-A receptors. Bromazolam acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor complex. It binds to the benzodiazepine recognition site located at the interface of alpha and gamma subunits, enhancing the inhibitory effects of GABA — the primary inhibitory neurotransmitter in the central nervous system — by increasing chloride ion conductance and thereby reducing neuronal excitability. The inclusion of the triazole ring in the triazolobenzodiazepine scaffold generally confers improved receptor binding affinity and metabolic resistance compared to classical benzodiazepines. The bromo substituent at the 8-position of the diazepine ring contributes to its distinct physicochemical profile. Primary metabolic routes include hydroxylation and glucuronidation, which have been characterised in analytical studies. Our Bromazolam is produced to 99%+ purity, confirmed by HPLC, NMR spectroscopy, and mass spectrometry. A comprehensive Certificate of Analysis is provided with every batch. It is used in GABA-A receptor pharmacology research, benzodiazepine binding studies, triazolobenzodiazepine SAR research, and forensic analytical reference standard development.